HIỆU QUẢ TIỆT TRỪ HELICOBACTER PYLORI CỦA PHÁC ĐỒ BỐN THUỐC CÓ BISMUTH VỚI PHÁC ĐỒ BA THUỐC CÓ LEVOFLOXACIN Ở BỆNH NHÂN VIÊM LOÉT DẠ DÀY TÁ TRÀNG ĐÃ THẤT BẠI ĐIỀU TRỊ

Abstract

Background: Helicobacter pylori (H.pylori) is a super-mutant bacteria that causes different immune responses in patients. Objectives: To evaluate the efficacy of H.pylori eradication of 4-drug regimens with Bismuth and 3-drug regimens with levofloxacin in patients with peptic ulcer disease who failed H.pylori treatment. Materials and methods: Descriptive study of a series of cases into 2 groups treated with 4-drug regimen containing Bismuth and group treated with 3-drug regimen containing Levofloxacin from June 2017 to August 2018. Patients were randomly selected when visiting on weekdays, at the outpatient department of Gastroenterology, Cho Ray Hospital. Results: 72.5% patients had a history of eradication failure 1 time, the history of using OAC regimen accounts for a higher rate than other regimens (50%.). Image of lesions on endoscopy: gastritis is the most common lesion (before treatment: 69.2% and after treatment 37.5%. The overall treatment response rate of the study was 88.3%. The rate of treatment response in group 3 drugs with Levofloxacin was 85,0%, group 4 drugs with bismuth was 91.7% (p > 0.05). The rate of side effects in the study was 101 cases (84.2%). Adherence to treatment had a statistically significant relationship with the treatment outcome (p < 0.001). Conclusion: Explain and guide the patient how to use the drug, and recommend prioritizing a 4-drug regimen with Bisthmus in patients with prior treatment failure.